Clinical Trial: A Single-Arm, Exploratory, Phase II Clinical Study of Trastuzumab Rezeteccan Combined with Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma Resistant to Antibody-Drug Conjugate Combined Immunotherapy (China)

China, Sept. 25 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Single-Arm, Exploratory, Phase II Clinical Study of Trastuzumab Rezeteccan Combined with Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma Resistant to Antibody-Drug Conjugate Combined Immunotherapy'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133387

Registration Time: 2026/09/24

Type: Interventional study

Primary Sponsor: Zhejiang Cancer Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=345238

Published by HT Digital Content Services with permission from Health Daily Digest....